HCM Marketplace

Pharmacogenomics (PGx) embodies the principles of personalized medicine by combining pharmacology with genetic information to improve drug safety and efficiency. The Pharma industry is currently applying PGx throughout its R&D processes to enhance decision-making, streamline clinical trial design and reduce drug failures and product withdrawals. Companies are also attempting to increase the impact of PGx by engaging in strategic alliances and collaborations. However, it is crucial that governments and regulators provide sufficient rewards for developers for innovation in this field to continue.

The new Business Insights' special report Impact of Pharmacogenomics on Public Healthcare Policy: Educating patients, payors, and healthcare providers examines how PGx implementations can help to improve efficiency and productivity within the industry, across the fields of pharma, biotech and diagnostics. The PGx strategies of major companies are profiled and recent alliances and licensing opportunities are highlighted. This report discusses how reimbursement issues may influence the uptake of PGx and assesses major regulatory issues in Europe, Japan and the US.

Discover the potential value of pharmacogenomics to your R&D program, identify the latest regulatory and reimbursement issues and benchmark PGx implementation strategies with this report...

Click here to view the seven-page executive summary of this report.

Use this new report as a platform to:

• Identify how companies are implementing PGx technologies with this report’s analysis of key strategies, alliances and licensing opportunities for major pharma, biotech and diagnostics firms.
  
• Discover how PGx can create cost-savings through improved decision-making and reduced development times by examining the challenges and opportunities facing this technology and assessing the realistically attainable benefits. 
• Understand the latest reimbursement issues influencing coverage, coding and payment in the PGx field by using this report’s profile of key reimbursement drivers and analysis of the cost-effectiveness and commercial viability of PGx tests and technologies. 
• Assess the extent to which changes in the regulatory landscape may influence future applications of PGx with this report’s analysis of influential white papers currently under review and major developments in the regulatory environments of Europe, Japan and the US. 
• Evaluate stakeholder importance in the uptake of PGx products and tests and understand how education and patient consent will affect PGx utilization in the drive towards personalized medicine.

Click here to view the seven-page executive summary of this report.

The report will be delivered as a PDF via e-mail. Orders must be paid in full before shipment. All sales are final; no returns or refunds are permitted with this product. For more information, please call 877/437-4276 or e-mail account manager Maureen Croce at mcroce@hcpro.com.

• Reports

• Other Marketing Products